Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors (BENEFIT-EXT)

Next Previous
X
Search
Trial Profile

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors (BENEFIT-EXT)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belatacept (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms BENEFIT-EXT
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 08 Jun 2022 Results assessing long-term allograft function between belatacept-based regimens and tacrolimus-based regimen up to five years from two clinical studies: BENEFIT and BENEFIT EXT presented at the 2022 American Transplant Congress
    • 08 Jun 2022 Results assessing the performances of the iBox system to capture this hemodynamic effect to predict long term graft survival in patients under a CNI free regimen in two studies (BENEFIT & BENEFIT EXT) presented at the 2022 American Transplant Congress.
    • 24 Dec 2019 Results of post-hoc analysis of patient-reported outcomes from the Phase III belatacept trials investigating the interrelationship between trajectories of HRQoL, symptom experience, and allograft outcomes published in the American Journal of Transplantation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top